semaglutide no longer available 🚨 FDA Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like and tirzepatide, signaling a major shift in how these Semaglutide shortage ends as FDA

1.69k views 37 slides Discovery of the Novel, Orally Active S1P 1 Receptor Agonist ACT-128800 (Ponesimod) Discovery of the Novel, Orally Active S1P 1 Receptor Agonist ACT-128800 (Ponesimod)

Turn social media influencers into affiliates As a storefront owner, you can create and share affiliate codes / links with social media influencers from the CareGLP platform

Therapeutic is defined by the Australian Therapeutic Goods Administration (TGA) as: * Influencing, inhibiting or modifying a physiological process in people or animals

The resolution of this apparent paradox is that glucagon receptor activation also drives energy expenditure through two well-documented mechanisms: Thermogenesis: GCGR activation in brown adipose tissue (BAT) and, to a lesser extent, skeletal muscle increases uncoupled heat production, raising resting energy expenditure

Paradoxically, this consumption of mucin appears to stimulate the gut to produce more mucin, potentially strengthening the gut barrier rather than weakening it

Pre-existing health conditions like insulin resistance from obesity may slow or reduce semaglutides effects on weight loss